表紙
市場調査レポート

ProMetic Life Sciences Inc. : 製品パイプライン分析

ProMetic Life Sciences Inc. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 203736
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
ProMetic Life Sciences Inc. : 製品パイプライン分析 ProMetic Life Sciences Inc. - Product Pipeline Review - 2016
出版日: 2016年07月30日 ページ情報: 英文 42 Pages
概要

ProMetic Life Sciences Inc. はバイオセパレーション技術、血漿由来治療、低分子薬剤を専門としたバイオ製薬会社です。

当レポートでは、Synthon BVにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを提供しています。ひと

ProMetic Life Sciences Inc.の基本情報

ProMetic Life Sciences Inc.の概要

  • 主要情報
  • 企業情報

ProMetic Life Sciences Inc.:R&Dの概要

  • 主な治療範囲

ProMetic Life Sciences Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

ProMetic Life Sciences Inc.:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第?相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第?相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

ProMetic Life Sciences Inc.:薬剤プロファイル

  • ヒト免疫グロブリン
  • PBI-1402
  • PBI-4050
  • ヒトプラスミノーゲン
  • α-1 ヒトプロティナーゼ阻害剤
  • PBI-0110
  • PBI-1393
  • PBI-1522
  • PBI-1668
  • PBI-1737
  • PBI-4419
  • PBI-4494
  • PBI-4547

ProMetic Life Sciences Inc.:パイプライン分析

  • 投与経路別
  • 分子タイプ別
  • 作用機序別

ProMetic Life Sciences Inc.:最近のパイプライン動向

ProMetic Life Sciences Inc.:休止中のプロジェクト

ProMetic Life Sciences Inc.:本社と子会社の所在地

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08108CDB

Summary

Global Markets Direct's, 'ProMetic Life Sciences Inc. - Product Pipeline Review - 2016', provides an overview of the ProMetic Life Sciences Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by ProMetic Life Sciences Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of ProMetic Life Sciences Inc.
  • The report provides overview of ProMetic Life Sciences Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses ProMetic Life Sciences Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features ProMetic Life Sciences Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate ProMetic Life Sciences Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for ProMetic Life Sciences Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding ProMetic Life Sciences Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ProMetic Life Sciences Inc. Snapshot
    • ProMetic Life Sciences Inc. Overview
    • Key Information
    • Key Facts
  • ProMetic Life Sciences Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • ProMetic Life Sciences Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • ProMetic Life Sciences Inc. - Pipeline Products Glance
    • ProMetic Life Sciences Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • ProMetic Life Sciences Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • ProMetic Life Sciences Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • ProMetic Life Sciences Inc. - Drug Profiles
    • immune globulin (human)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • plasminogen (human)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PBI-4050
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alpha-1 proteinase inhibitor (human)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • C1 esterase inhibitor (human)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PBI-4419
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PBI-4425
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PBI-4547
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • plasminogen (recombinant)
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ProMetic Life Sciences Inc. - Pipeline Analysis
    • ProMetic Life Sciences Inc. - Pipeline Products by Target
    • ProMetic Life Sciences Inc. - Pipeline Products by Route of Administration
    • ProMetic Life Sciences Inc. - Pipeline Products by Molecule Type
    • ProMetic Life Sciences Inc. - Pipeline Products by Mechanism of Action
  • ProMetic Life Sciences Inc. - Recent Pipeline Updates
  • ProMetic Life Sciences Inc. - Dormant Projects
  • ProMetic Life Sciences Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ProMetic Life Sciences Inc., Key Information
  • ProMetic Life Sciences Inc., Key Facts
  • ProMetic Life Sciences Inc. - Pipeline by Indication, 2016
  • ProMetic Life Sciences Inc. - Pipeline by Stage of Development, 2016
  • ProMetic Life Sciences Inc. - Monotherapy Products in Pipeline, 2016
  • ProMetic Life Sciences Inc. - Partnered Products in Pipeline, 2016
  • ProMetic Life Sciences Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • ProMetic Life Sciences Inc. - Phase III, 2016
  • ProMetic Life Sciences Inc. - Phase II, 2016
  • ProMetic Life Sciences Inc. - Phase I, 2016
  • ProMetic Life Sciences Inc. - Preclinical, 2016
  • ProMetic Life Sciences Inc. - Pipeline by Target, 2016
  • ProMetic Life Sciences Inc. - Pipeline by Route of Administration, 2016
  • ProMetic Life Sciences Inc. - Pipeline by Molecule Type, 2016
  • ProMetic Life Sciences Inc. - Pipeline Products by Mechanism of Action, 2016
  • ProMetic Life Sciences Inc. - Recent Pipeline Updates, 2016
  • ProMetic Life Sciences Inc. - Dormant Developmental Projects,2016
  • ProMetic Life Sciences Inc., Other Locations
  • ProMetic Life Sciences Inc., Subsidiaries

List of Figures

  • ProMetic Life Sciences Inc. - Pipeline by Top 10 Indication, 2016
  • ProMetic Life Sciences Inc. - Pipeline by Stage of Development, 2016
  • ProMetic Life Sciences Inc. - Monotherapy Products in Pipeline, 2016
  • ProMetic Life Sciences Inc. - Pipeline by Target, 2016
  • ProMetic Life Sciences Inc. - Pipeline by Route of Administration, 2016
  • ProMetic Life Sciences Inc. - Pipeline by Molecule Type, 2016
  • ProMetic Life Sciences Inc. - Pipeline Products by Mechanism of Action, 2016
Back to Top